Abstract:Abstract Background: Primary testicular lymphomas (PTLs) are extra-nodal large B-cell lymphomas (LBCLs) that respond poorly to current empirical treatment options. To date, no PTL whole-exome sequencing analysis based on the Chinese population has been reported. The main objective of this study was to explore the genomic landscape of PTDLBCL, correlating the results with clinical, histological, and immunogenetic features. Methods: We retrospectively analyzed the disease characteristics in a series of 20 patients (13 paired data and 7 unpaired data). In all cases, the diagnosis of PTL was made using appropriate diagnostic criteria for the 2008 WHO classification of lymphoid tumors with combinations of histologic, immunohistochemical, flow cytometric, and genetic evaluation. Medical records were reviewed for demographic and clinical data. We performed whole-exome next-generation sequencing (NGS) and mapped the mutational landscape. Based on the differential gene results, we performed KEGG and GO enrichment analysis, and five potential new pathogenic genes for DLBCL were obtained based on the Polyphen score. Results: A total of 20 DLBCL samples were collected. All samples were subjected to whole-exome sequencing (WES). A standard bioinformatics analysis process was used to identify somatic mutations in each sample, and an average of 1200 somatic mutations was identified, involving an average of 420 mutated genes. (Figure 1.) More than 85% of the somatic mutations were found in only 1 sample, indicating that somatic mutations are highly heterogeneous. In the matched 13 cases, we validated common gene mutations that have been reported, including PIM1 53.84% (7/13), CD79B 38.46% (5/13), CDKN2A 15.38% (2/13), and MYD88 15.38% (2/13). Venn diagram shows that 25% of the mutated genes were specific to the relapsed sample. GO analysis (Figure 2) shows the functional enrichment and differences between relapsed and non-relapsed samples. Non-relapsed samples are enriched in the herpes simplex virus 1 infection pathway. (Figure 3). Focusing on relapsed/non-relapsed samples, we identified 12 mutated genes specific to relapsed samples. Mutation Polyphen scores were calculated to assess mutation deleteriousness. Five potential new pathogenic genes for DLBCL were obtained. Conclusions: Based on whole-sequencing data, we validated the previously reported common genes for PTDLBCL. In addition, we performed GO and KEGG analysis according to the relapsed and non-relapsed groups. In addition, based on the difference in enrichment results, 12 significantly enriched mutated genes in relapsed DLBCL samples are obtained, and mutation Polyphen scores are calculated to assess mutation deleteriousness. And 5 potential new pathogenic genes of DLBCL are identified. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma

Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma

Prognostic Effects of Clinical Parameters, Genetic Abnormalities, and Subtypes in Primary Gastric Diffuse Large B-cell Lymphoma: a Cohort Analysis of 146 Patients

Molecular Biomarker Exploration of Rituximab plus CHOP Therapy in Real-World Diffuse Large B-Cell Lymphoma Patients

[Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas]

Next-Generation Sequencing Reveals Molecular Heterogeneity in Primary Testicular DLBCL

[Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma]

[Clinicopathological characteristics and prognostic analysis of 92 cases with primary gastrointestinal diffuse large B-cell lymphoma].

Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database

[Long Term Follow-Up and Prognostic Analysis of 85 Cases with Primary Gastrointestinal Diffuse Large B Cell Lymphoma].

Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL

Immunohistochemical Classification and Prognosis of Diffuse Large B-cell Lymphoma in China

Primary intestinal diffuse large B-cell lymphoma: novel insights and clinical perception

Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma

Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing

Clinical Analysis of Primary Gastric Diffuse Large B-cell Lymphoma

CLINICAL FEATURES AND PROGNOSES OF PRIMARY GASTRIC DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF 139 CHINESE CASES WITH IMMUNOPHENOTYPING FROM CLAP

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

Clinical analysis of 69 patients with primary gastric diffuse large B-cell lymphoma

Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma

Development and validation of prognostic scoring in primary intestinal diffuse large B-cell lymphoma: a single-institution study of 184 patients